A Phase Ib/II trial of daratumumab in combination with nivolumab in patiens with relapsed or refractory multiple myeloma
Latest Information Update: 09 Jan 2017
Price :
$35 *
At a glance
- Drugs Daratumumab (Primary) ; Nivolumab (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 09 Jan 2017 New trial record
- 05 Jan 2017 According to a Janssen Biotech media release, this trial is expected to initiate in 2017.